UNSPSC 51263127: Talinolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H33N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3S82268BKG, chemically known as urea, n-cyclohexyl-n-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)- but generally known as talinolol, which bears US NIH Compound Identifier 68770. European Medicines Agency schedules Talinolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10804MIG.

UNSPSC 51263127 Talinolol is a Commodity code nominally identifying a specific beta-blocker pharmaceutical, but recent state and local opportunities tagged under it do not reflect procurement of talinolol itself. Instead, the code appears in solicitations for naloxone (opioid-reversal medication) and pharmacy benefit program infrastructure. Seminole County, Florida posted an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the county's community health building and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities for implementing a direct-to-manufacturer prescription program designed to bypass traditional pharmacy benefit managers and group purchasing organizations. The issuing bodies are primarily state health and human services departments and county public health agencies; the code shows limited recent activity and the mismatch between its nominal scope and actual procurement suggests either miscoding by the sourcing jurisdictions or a secondary use of the code for broader pharmaceutical procurement categories.

Geographic activity is concentrated in Florida and Texas based on the two recent opportunities. Seminole County's naloxone procurement (IFB60459723LAS, response due July 26, 2023) is a routine public health supply buy with standard insurance, E-Verify, and drug-free workplace compliance requirements. The Texas HHS RFI (HHS0017013, April 2026) is exploratory market research rather than a competitive solicitation and carries no award value or timeline; it precedes formal specification development and is designed to inform the state's future procurement strategy for direct-to-manufacturer pharmacy relationships. The code shows no current activity in other states or local jurisdictions beyond these two opportunities, and the substantial divergence between the code's pharmaceutical name and the actual work being solicited suggests caution in relying on this code as a reliable signal for pharmaceutical procurement planning.